Antibodies specific for CD44v6

Details Antibodies specific for CD44v6 Antibodies specific for CD44v6

2005-12-06

2005-12-06

Helms, Larry R. (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387300, C530S391300, C424S133100, C424S156100

Reexamination Certificate

active

06972324

ABSTRACT:
The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.

REFERENCES:
patent: 4897255 (1990-01-01), Fritzberg et al.
patent: 5082930 (1992-01-01), Nicolotti et al.
patent: 5242679 (1993-09-01), Fritzberg et al.
patent: 5616468 (1997-04-01), Salmi et al.
patent: 5648267 (1997-07-01), Reff
patent: 5681927 (1997-10-01), Fritzberg et al.
patent: 5733779 (1998-03-01), Reff
patent: 5916561 (1999-06-01), Adolf et al.
patent: 6010865 (2000-01-01), Ponta et al.
patent: 6338835 (2002-01-01), Shochat et al.
patent: 726704 (1997-06-01), None
patent: 2281934 (1998-09-01), None
patent: 0 188 256 (1986-07-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 247 866 (1987-12-01), None
patent: 0 284 071 (1988-09-01), None
patent: 0284071 (1988-09-01), None
patent: 0 368 684 (1990-05-01), None
patent: 0 438 310 (1991-07-01), None
patent: 0 481 790 (1992-04-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/05274 (1992-04-01), None
patent: WO 92/07075 (1992-04-01), None
patent: WO 92/11018 (1992-07-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 93/05804 (1993-04-01), None
patent: WO 94/11523 (1994-05-01), None
patent: WO 94/12631 (1994-06-01), None
patent: WO 95/00851 (1995-01-01), None
patent: WO 95/33771 (1995-12-01), None
patent: WO 97/09351 (1997-03-01), None
patent: WO 97/21104 (1997-06-01), None
patent: WO 98/39034 (1998-09-01), None
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Rudikoff et al., PNAS 79:1979, 1982.
Rieger et al., Glossary of Genetics of Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976.
Boulianne, G.L., et al., “Production of functional chimaeric mouse/human antibody,”Nature 312:643-646, Macmillan Publishers, Ltd. (1984).
Chothia, C., and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol. 196:901-917, Academic Press, Ltd. (1987).
Günthert, U., et al., “A New Variant of Glycoprotein CD44 Confers Metastatic Potential to Rat Carcinoma Cells,”Cell 65:13-24, Cell Press (1991).
Haisma, H.J., et al., “Iodination of Monoclonal Antibodies for Diagnosis and Radiotherapy Using a Convenient One Vial Method,”J. Nucl. Med. 27:1890-1895, The Society of Nuclear Medicine, Inc. (1986).
Hayden, M.A., and Mandecki, W., “Laboratory Methods. Gene Synthesis by Serial Cloning of Oligonucleotides,”DNA 7:571-577, Mary Ann Liebert, Inc. (1988).
Heider, K.-H., et al., “A Human Homologue of the Rat Metastasis-associated Variant of CD44 is Expressed in Colorectal Carcinomas and Adenomatous Polyps,”J. Cell. Biol. 120:227-233, Rockefeller University Press (1993).
Heider, K.-H., et al., “Differential Expression of CD44 Splice Variants in Intestinal- and Diffuse-Type Human Gastric Carcinomas and Normal Gastric Mucosa,”Cancer Res. 53:4197-4203, American Association for Cancer Research (1993).
Heider, K.-H., et al., “Splice Variants of the Cell Surface Glycoprotein CD44 Associated with Metastatic Tumour Cells are Expressed in Normal Tissues of Humans and Cynomolgus Monkeys,”Eur. J. Cancer 31A:2385-2391, Elsevier Science, Ltd. (1995).
Heider, K.-H., et al., “Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas,”Cancer Immunol. Immunother. 43:245-253, Springer-Verlag (1996).
Himmler, A., et al., “Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein,”DNA Cell Biol. 9:705-715, Mary Ann Liebert, Inc. (1990).
Hofmann, M., et al., “CD44 Splice Variants Confer Metastatic Behavior in Rats: Homologous Sequences Are Expressed in Human Tumor Cell Lines,”Cancer Res. 51:5292-5297, American Association for Cancer Research (1991).
Huston, J.S., et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain FV analogue produced inEscherichia coli,” Proc. Natl. Acad. Sci. USA 16:5879-5883, National Academy Press (1988).
Hu, Shi-zhen, et al., “Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3) Which Exhibits Rapid, High-Level Targeting of Xenografts,”Cancer Res. 56:3055-3061, American Association For Cancer Research (1996).
Koopman, G., et al., “Activated Human Lymphocytes and Aggressive Non-Hodgkin's Lymphomas Express a Homologue of the Rat Metastasis-associated Variant of CD44,”J. Exp. Med. 177:897-904, Rockefeller University Press (1993).
Kortt, A.A., et al., “Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer,”Protein Eng. 10:423-433, Oxford University Press (1997).
Kugelman, L.C., et al., “The Core Protein of Epican, a Heparan Sulfate Proteoglycan on Keratinocytes, Is an Alternative Form of CD44,”J. Invest. Dermatol. 99:887-891, Society for Investigative Dermatology, Inc. (1992).
LoBuglio, A.F., et al., “Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response,”Proc. Natl. Acad. Sci. USA 86:4220-4224, National Academy Press (1989).
Lovejoy, B., et al., “Crystal Structure of a Synthetic Triple-Stranded α-Helical Bundle,”Science 259:1288-1293, American Association for the Advancement of Science (1993).
Pack, P., et al., “Improved Bivalent Miniantibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation ofEscherichia coli,” Bio/technology 11:1271-1277, Nature Publishing Company (1993).
Pack, P., et al., “Tetravalent Miniantibodies with High Avidity Assembling inEscherichia coli,” J. Mol. Biol. 246:28-34, Academic Press, Ltd. (1995).
Perisic, O., et al., “Crystal structure of a diabody, a bivalent antibody fragment,”Structure 2:1217-1226, Current Biology, Ltd. (1994).
Queen, C., et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA 66:10029-10033, National Academy Press (1989).
Riechmann, L., et al., “Reshaping human antibodies for therapy,”Nature 332:323-327, Macmillan Publishers, Ltd. (1988).
Rudy, W., et al., “The Two Major CD44 Proteins Expressed on a Metastatic Rat Tumor Cell Line Are Derived from Different Splice Variants: Each One Individually Suffices to Confer Metastatic Behavior,”Cancer Res. 53:1262-1268, American Association for Cancer Research (1993).
Screaton, G.R., et al., “Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons,”Proc. Natl. Acad. Sci. USA 89:12160-12164, National Academy Press (1992).
Seiter, S., et al., “Prevention of Tumor Metastasis Formation by Anti-Variant CD44,”J. Exp. Med. 177:443-455, Rockefeller University Press (1993).
Sharkey, R.M., et al., “Rapid Blood Clearance of Immunoglobulin G2a and Immunoglobulin G2b in Nude mice,”Cancer Res. 51:3102-310, American Association for Cancer Research (1991).
Stemmer, W.P.C., et al., “Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides,”Gene 164:49-53, Elsevier Science B.V. (1995).
Stroomer, J.W.G., et al., “Safety and Biodistribution of99mTe

Affiliated with

Also associated with

Rating

Antibodies specific for CD44v6 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies specific for CD44v6, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies specific for CD44v6 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3522357